Human menopausal gonadotropin versus recombinant FSH in polycystic ovary syndrome patients undergoing in vitro fertilization

International Journal of Fertility and Sterility

Volumn 6, Issue 4, 2013, Pages 238-243

  Turkcapar, Ayse Figen ^a   Seckin, Berna ^a   Onalan, Gogsen ^b   Ozdener, Tulin ^a   Batioglu, Sertac ^a  

^a ZEKAI TAHIR BURAK WOMEN S HEALTH EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

hMG; In vitro fertilization; Polycystic ovary syndrome; Recombinant FSH

Indexed keywords

ESTRADIOL; GONADORELIN; HUMAN MENOPAUSAL GONADOTROPIN; LEUPRORELIN; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; EMBRYO TRANSFER; ENDOMETRIAL THICKNESS; FEMALE; FERTILIZATION; FERTILIZATION IN VITRO; FOLLOW UP; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; MAJOR CLINICAL STUDY; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

EID: 84874770206     PISSN: 2008076X     EISSN: 20080778     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Brinsden PR, Wada I, Tan SL, Balen A, Jacobs HS. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol. 1995; 102(10): 767-772.
2. Lin K, Coutifaris C. In vitro fertilization in the polycystic ovary syndrome patient: an update. Clin Obstet Gynecol. 2007; 50(1): 268-276.
3. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH ceiling? Hum Reprod. 2003; 18(12): 2719-2720.
4. Larsen T, Larsen JF, Schiøler V, Bostofte E, Felding C. Comparison of urinary human follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in polycystic ovarian syndrome. Fertil Steril. 1990; 53(3): 426-431.
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41-47.
6. The Practice Committee of the American Society for American Society for Reproductive Medicine (ASRM). Ovarian hyperstimulation syndrome. Fertil Steril. 2008; 90 Suppl 5: 188-193.
7. Soares SR, Gómez R, Simón C, García-Velasco JA, Pellicer A. Targeting the vascular endothelial growth factor system to prevent ovarian hyperstimulation syndrome. Hum Reprod Update. 2008; 14(4): 321-333.
8. Filicori M, Cognigni GE, Tabarelli C, Pocognoli P, Taraborrelli S, Spettoli D, et al. Stimulation and growth of antral ovarian follicles by selective LH activity administration in women. J Clin Endocrinol Metab. 2002; 87(3): 1156-1161.
9. Platteau P, Andersen AN, Balen A, Devroey P, Sørensen P, Helmgaard L, et al. Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Hum Reprod. 2006; 21(7): 1798-1804.
10. Smitz J, Andersen AN, Devroey P, Arce JC, MERIT Group. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. Hum Reprod. 2007; 22(3): 676-687.
11. Loumaye E, Engrand P, Shoham Z, Hillier SG, Baird DT. Clinical evidence for an LH 'ceiling' effect induced by administration of recombinant human LH during the late follicular phase of stimulated cycles in World Health Organization type I and type II anovulation. Hum Reprod. 2003; 18(2): 314-322.
12. Hugues JN, Soussis J, Calderon I, Balasch J, Anderson RA, Romeu A, Recombinant LH Study Group. Does the addition of recombinant LH in WHO group II anovulatory women over-responding to FSH treatment reduce the number of developing follicles? A dose-finding study. Hum Reprod. 2005; 20(3): 629-635.
13. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Hum Reprod. 2006; 21(12): 3217-3227.
14. Daya S. Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertil Steril. 2002; 77(4): 711-714.
15. van Wely M, Westergaard LG, Bossuyt PM, van der Veen F. Effectiveness of human menopausal go-nadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertil Steril. 2003; 80(5): 1086-1093.
16. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008; 23(2): 310-315.
17. Van Wely M, Westergaard LG, Bossuyt PM, Van der Veen F. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2003; (1): CD003973.
18. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008; 16(1): 81-88.
19. Al-Inany HG, Abou-Setta AM, Aboulghar MA, Mansour RT, Serour GI. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with recombinant FSH: a meta analysis. Gynecol Endocrinol. 2009; 25(6): 372-378.
20. Torabizadeh A. The comparison of the IVF outcome between three methods of induction ovulation in PCOS patients. Int J Fertil Steril. 2010; 4 Suppl 1:P67.